FDA, EU agree to review Biogen's MS drug Plegridy

07/22/2013 | Pharmaceutical Business Review Online · PMLive.com (U.K.)

The FDA and the European Medicines Agency have accepted Biogen Idec's marketing applications for Plegridy, or peginterferon beta-1a, a subcutaneous injectable formulation for the treatment of relapsing forms of multiple sclerosis. The applications included data from the late-stage ADVANCE trial.

View Full Article in:

Pharmaceutical Business Review Online · PMLive.com (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN